![]() ![]() "Clearly we need more than just one medication - women need to have an array of choices that meets their specific medical needs," says Terry O'Neill of the National Organization for Women. The decision was welcomed by some doctors and women's advocates, who said they hoped it would open to the door to more drugs to help women with sexual problems. In June, Sprout finally convinced an FDA advisory committee to recommend the drug's approval by providing new studies to show it can safely boost a woman's sex drive, enabling them to have more satisfying sexual experiences. ![]() "For far too long we've reduced all things in the bedroom for men to biology, as witnessed by countless treatment options, and we've reduced all things for women to psychology," Whitehead says. The company and its supporters had essentially accused the FDA of being sexist for rejecting the drug twice before while approving Viagra and other drugs to help men with their sexual problems. The pill has long history of controversy. And I'm thrilled that today the decision is finally being turned over to women and their health care providers regarding their sexual health." "For decades, millions of women have been waiting for a medical solution to restore their sexual desire. "Addyi is a game changer, in my opinion, for women's health," said Cynthia Whitehead, Sprout's CEO. The medicine is to be taken daily to treat premenopausal women suffering from hypoactive sexual desire disorder, which is essentially a sudden, unexplained loss of any desire to have sex. 17, according to its maker, Sprout Pharmaceuticals. The little pink pill, known generically as flibanserin, will be sold under the brand name Addyi beginning Oct. The controversial decision was hailed by some doctors and advocates as a long-sought victory for women's health, but was condemned by others as irresponsible and dangerous. The Food and Drug Administration approved the first drug designed to increase a woman's libido. "Sexual harassment and gender discrimination findings: Active component," in National Defense Research Institute, Sexual Assault and Sexual Harassment in the U.S.A daily pill called Addyi is the first medicine to be approved for the purpose of boosting women's sexual desire. Armed Forces, RAND Corporation (RR-2167), 2018įarris, C., Jaycox, L. Matthews, Miriam, Coreen Farris, Margaret Tankard, and Michael Stephen Dunbar, Needs of Male Sexual Assault Victims in the U.S. Miller, Peter Glick, Katharine Sieck, and Radha Iyengar Plumb, Availability of Family Violence Services for Military Service Members and Their Families, RAND Corporation (RR-3019), 2019 Iyiewuare, Lynn Rosenthal, Angela Clague, Laura L. Jaycox, Barbara Bicksler, Angela Clague, and Dionne Barnes-Proby, Measures of Performance and Effectiveness for the Marine Corps' Sexual Assault Prevention Programs, RAND Corporation (RR-2220), 2019įarris, Coreen, Margaret Tankard, Praise O. Schell, Miriam Matthews, Sierra Smucker, Samantha Cohen, and Owen Hall, Harassment and Discrimination on the Basis of Gender and Race/Ethnicity in the FEMA Workforce, RAND Corporation (RR-A383-1), 2020įarris, Coreen, Terry L. ![]() Military: Findings from the RAND Military Workplace Study, RAND Corporation (RR-3162), 2021įarris, Coreen, Carra S. Morral, The Relationship Between Sexual Assault and Sexual Harassment in the U.S. Schell, Terry L., Matthew Cefalu, Coreen Farris, and Andrew R. Military, RAND Corporation (RR-4241), 2021 Schell, Healthy Relationship Approaches to Sexual Assault Prevention: Programs and Strategies for Use Within the U.S. Trail, Samuel Peterson, Brandon Crosby, and Terry L. Beckman, Perceived Retaliation Against Military Sexual Assault Victims, RAND Corporation (RR-2380), 2021įarris, Coreen, Melissa M. ![]()
0 Comments
Leave a Reply. |